Delving into the Latest Updates on COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine, Genetically engineered subunit vaccine

Synonyms

Omicron XBB.1.5 Vaccine(Clover Biopharmaceuticals AUS), SCB-2023

Target

SARS-CoV S protein

Action

inhibitors, stimulants

Mechanism

SARS-CoV S protein inhibitors(SARS-CoV S protein inhibitors), Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

COVID-19

Originator Organization

Clover Biopharmaceuticals AUS Pty Ltd.

Active Organization-

Inactive Organization

Clover Biopharmaceuticals AUS Pty Ltd.

License Organization-

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Twenty-five recipients of the XBB.1.5 vaccine, categorized as seronegative (n = 18) or seropositive (n = 7) based on their recent history of COVID-19, were analyzed. Neutralizing antibody titers against Omicron subvariants, receptor binding domain (RBD) IgG levels, IgG subclass distribution, and T-cell responses were assessed.

RESULTS:

We found a significant increase in neutralizing antibody titers against XBB.1.5 and BA.2.86 variants following XBB.1.5 vaccination, particularly in seropositive individuals. No significant change in total RBD IgG levels was observed, indicating efficient induction of antibodies targeting regions outside the RBD by XBB.1.5 vaccination. IgG subclass analysis demonstrated no significant subclass switching after vaccination. T-cell responses against the virus were comparable between seropositive and seronegative groups.

CONCLUSIONS:

The study suggests that XBB.1.5 vaccination enhances humoral immunity against Omicron variants without significant IgG subclass switching. However, some individuals with low pre-vaccination IgG titers did not exhibit increased antibody levels post-vaccination, raising concerns about potential immune tolerance.

07 Mar 2024·Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Article

Author: de Gier, Brechje ; Knol, Mirjam J ; van der Veer, Bas ; Hoeve, Christina E ; van de Wijgert, Janneke HHM ; Cremer, Jeroen ; Eggink, Dirk ; de Melker, Hester E ; Huiberts, Anne J ; van den Hof, Susan

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8–2.6).

15 Feb 2024·Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)

Article

Author: Levade, Inès ; Kaweski, Samantha E ; Mather, Richard G ; Olsha, Romy ; Skowronski, Danuta M ; Sabaiduc, Suzana ; Jassem, Agatha N ; Gao, Ruimin ; Khalid, Ayisha ; Charest, Hugues ; Dickinson, James A ; Zhan, Yuping ; Bastien, Nathalie ; Carazo, Sara ; Zelyas, Nathan ; Hasso, Maan

The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).

100 Deals associated with COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS)

Login to view more data